Author/Authors :
Nowroozi، Mohamadreza نويسنده Uro-Oncology Research Center, Tehran University of Medical
Sciences, Tehran, IR Iran , , Ayati، Mohsen نويسنده , , Haji-Mohammadmehdi-Arbab، Amir نويسنده , , Jamshidian، Hassan نويسنده , , Ghorbani، Hamidreza نويسنده Department of Urology, Qazvin University of Medical
Sciences, Qazvin, IR Iran , , Niroomand، Hassan نويسنده Urology Research Center, Guilan University of Medical Sciences, Rasht , , Taheri Mahmoodi، Mohsen نويسنده Uro-Oncology Research Center, Tehran University of Medical
Sciences, Tehran, IR Iran , , Amini، Erfan نويسنده Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. , , Salehi، Sohrab نويسنده Department of Urology, Qazvin University of Medical
Sciences, Qazvin, IR Iran , , Hakima، Hamid نويسنده Department of Urology, Qazvin University of Medical
Sciences, Qazvin, IR Iran , , Fazeli، Farid نويسنده Uro-Oncology Research Center, Tehran University of Medical
Sciences, Tehran, IR Iran , , Haghdani، Saeid نويسنده , , Ghadian، Alireza نويسنده ,
Abstract :
Testicular cancer accounts for about 1 - 1.5% of all malignancies in men. Radical orchiectomy is curative in 75% of patients with stage I disease, but advance stage with retroperitoneal lymph node involvement needs chemotherapy. All patients who have residual masses ? 1 cm after chemotherapy should undergo postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). Treatment of advanced nonseminomatous testicular cancer is usually a combination of chemotherapy and surgery. We described our experience about postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in our center. In a retrospective cross-sectional study between 2006 and 2011, patients with a history of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in Imam Khomeini hospital were evaluated. All patients had normal postchemotherapy serum tumor markers and primary nonseminomatous cancer. We reviewed retrospectively clinical, pathological, and surgical parameters associated with PC-RPLND in our center. Twenty-one patients underwent bilateral PC-RPLND. Mean age was 26.3 years (ranged 16 - 47). Mean size of retroperitoneal mass after chemotherapy was 7.6 cm. Mean operative time was 198 minutes (120 - 246 minutes). Mean follow-up time was 38.6 months. Pathologic review showed presence of fibrosis/necrosis, viable germ cell tumor and teratoma in 8 (38.1%), 10 (47.6%) and 3 (14.28%) patients, respectively. One patient in postoperative period of surgery and three patients in two first years after surgery were expired. Of 17 alive patients, only two (11.8%) had not retrograde ejaculation. PC-RPLND is one the major operations in the field of urology, which is associated with significant adjunctive surgeries. In appropriate cases, PC-RPLND was associated with good cancer specific survival in tertiary oncology center
